|
|
Stevanato Group S p a (NYSE: STVN) |
|
Price: $21.8000
$0.26 
1.207%
|
| Day's High:
| $21.950000762939453
| Week Perf:
| 4.06 %
|
| Day's Low: |
$ 21.43 |
30 Day Perf: |
2.54 % |
| Volume (M): |
195,460 |
52 Wk High: |
$ 28.00 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$19.58 |
| Open: |
$21.51 |
52 Wk Low: |
$12.89 |
|
|
| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
6,010 |
| Revenues (TTM) (Millions $) |
1,329 |
| Net Income (TTM) (Millions $) |
157 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
295 |
Business Description
Stevanato Group S.p.A is a global producer of glass primary packaging and provider of integrated solutions for the pharmaceutical and healthcare industries. With headquarters in Italy, the company specializes in the design, development, and production of glass containers and drug delivery systems including pre-filled syringes, vials, cartridges, and specialty products. Stevanato Group also offers a range of services such as analytical testing, customized solutions, and digital applications to support the pharmaceutical industry. The company is known for its focus on innovation, quality, and sustainability, serving customers worldwide.
Company Address: Via Molinella 17 Piombino Dese – Padua 35017
Company Phone Number: 049 931811 Stock Exchange / Ticker: NYSE STVN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, Oct 1 2024 12:47 PM UTC
In a bold move poised to reshape the landscape of injectable therapies, Stevanato Group S.p.A. (NYSE: STVN), a distinguished leader in the realms of drug containment and delivery solutions, has announced the expansion of its innovative Vertiva platform with the introduction of a robust 10mL On-Body Delivery System. This significant development will be showcased at the upcomi...
|
| Business Update
Published Thu, Sep 26 2024 11:47 AM UTC
Piombino Dese, Italy In a significant development for the pharmaceutical, biotechnology, and life sciences sectors, Stevanato Group S.p.A. (NYSE: STVN), a leading global provider in drug containment, delivery, and diagnostic solutions, has announced a strategic alliance with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP). This collaboration, term...
|
| Business Update
Published Thu, May 30 2024 10:44 AM UTC
Stevanato Group Expands Operations with New State-of-the-Art Plant in Cisterna di LatinaPIOMBINO DESE, Italy - Stevanato Group S.p.A. (NYSE: STVN), a renowned global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, has announced the opening of its cutting-edge plant in Cisterna di Latina....
|
| Business Update
Published Mon, May 27 2024 3:41 AM UTC
Stevanato Group Unveils Milestone Achievements at Annual General MeetingPIOMBINO DESE, Italy Stevanato Group S.p.A. (NYSE: STVN), a globally recognized leader in drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, has proudly announced that all resolutions proposed to the shareholders at the Annual...
|
| Business Update
Published Sun, May 26 2024 6:39 AM UTC
Stevanato Group Unanimously Approves Resolutions at Annual General MeetingStevanato Group S.p.A. (NYSE: STVN), a leading global provider of innovative drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, has announced the successful passing of all resolutions proposed to shareholders during its Annual ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
221,071 |
| Net
Income per Employee (TTM) |
26,058 |
| Receivable Turnover Ratio (TTM) |
3.92 |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
0.47 |
|
|
| Per Share |
|
| Earnings (TTM) |
0 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| Total Segments |
|
 111.39 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions |
|
87.51 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions Customer |
|
10.74 % |
of total Revenue |
| External Customers |
|
100 % |
of total Revenue |
| Adjustments Eliminations and Unallocated Items |
|
-10.1 % |
of total Revenue |
| Adjustments Eliminations and Unallocated Items Inter-Segment |
|
-11.39 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions External Customers |
|
87.51 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions Inter-Segment |
|
0.18 % |
of total Revenue |
| Engineering |
|
12.49 % |
of total Revenue |
| Engineering External Customers |
|
12.49 % |
of total Revenue |
| Engineering Inter-Segment |
|
11.2 % |
of total Revenue |
| Total External Customers |
|
100 % |
of total Revenue |
| Total Inter-Segment |
|
11.39 % |
of total Revenue |
| High-Value Solutions |
|
46.06 % |
of total Revenue |
| Other Containment and Delivery Solutions |
|
41.46 % |
of total Revenue |
| Revenue from Engineering |
|
12.49 % |
of total Revenue |
| EMEA |
|
58.19 % |
of total Revenue |
| APAC |
|
8.55 % |
of total Revenue |
| North America |
|
30.52 % |
of total Revenue |
| South America |
|
2.73 % |
of total Revenue |
| Goods and Services Transferred at a Point in Time |
|
87.27 % |
of total Revenue |
| Goods and Services Transferred Over Time |
|
12.73 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions High-Value Solutions |
|
46.06 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions Other Containment and Delivery Solutions |
|
41.46 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions EMEA |
|
49.33 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions APAC |
|
7.39 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions North America |
|
28.27 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions South America |
|
2.52 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions Goods and Services Transferred at a Point in Time |
|
85.01 % |
of total Revenue |
| Biopharmaceutical and Diagnostic Solutions Goods and Services Transferred Over Time |
|
2.5 % |
of total Revenue |
| Engineering Revenue from Engineering |
|
12.49 % |
of total Revenue |
| Engineering EMEA |
|
8.86 % |
of total Revenue |
| Engineering APAC |
|
1.16 % |
of total Revenue |
| Engineering North America |
|
2.25 % |
of total Revenue |
| Engineering South America |
|
0.21 % |
of total Revenue |
| Engineering Goods and Services Transferred at a Point in Time |
|
2.26 % |
of total Revenue |
| Engineering Goods and Services Transferred Over Time |
|
10.23 % |
of total Revenue |
| Italy |
|
7.87 % |
of total Revenue |
|
|
2.47%